33 employees
KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents.
2007
$2M
from 2 investors over 2 rounds
KromaTiD™ Inc. raised $2M on April 28, 2021
Investors: BroadOak Capital Partners
KromaTiD™ Inc. raised undisclosed on August 13, 2019
Investors: First Capital Business Development, LLC.